ICCC vs WY · rev $17.5M vs P/E 43, rev $3.59B
ImmuCell Corporation (ICCC) versus Weyerhaeuser Company (WY) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Weyerhaeuser Company (WY) is a reit - specialty company listed on NYSE.
Latest reported ICCC revenue for 2026-06-30 was $17.5M. Net income was $3.8M. Revenue was up 69.4% from 2026-03-31 to 2026-06-30. ICCC currently screens at market cap $58.9M.
Latest reported WY revenue for 2026-06-30 was $3.59B. Net income was $318.0M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
ICCC currently screens at market cap $58.9M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
Not investment advice. Open the ICCC and WY stock pages for the full models.
Not investment advice.